Two patients who developed refractory sclerodermatous cGVHD following allo-SCT received imatinib mesylate at the dose of 400 mg/day. In both patients, the scleroderma symptoms disappeared within ...

Nilotinib in imatinib mesylate-resistant or intolerant accelerated chronic myeloid leukemia. A Phase II trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...